Oxurion NV (FRA:TG40) Total Receivables: €0.38 Mil (As of Dec. 2025)


What is Oxurion NV Total Receivables?

Oxurion NV FRA:TG40 Total Receivables is €0.38 Mil as of Dec. 2025. The stock has 7 warning signs investors should review.

Oxurion NV's Total Receivables for the quarter that ended in Dec. 2025 was €0.38 Mil.

Oxurion NV Total Receivables Historical Data

* Premium members only.

The historical data trend for Oxurion NV's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oxurion NV Total Receivables Chart

Oxurion NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Receivables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.36 3.01 0.82 2.36 0.38

Oxurion NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.82 0.57 2.36 2.16 0.38

Oxurion NV Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of €0.38 Mil mean?
Oxurion NV (FRA:TG40) has a Total Receivables of €0.38 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Oxurion NV and its competitors.
Is Oxurion NV's Total Receivables too high?
Oxurion NV's current Total Receivables is €0.38 Mil.
How does Oxurion NV's Total Receivables compare to VRTX and REGN?
Oxurion NV's Total Receivables of €0.38 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Biotechnology company?
A good Total Receivables depends on the Biotechnology industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on Oxurion NV and its competitors. Oxurion NV's current Total Receivables is €0.38 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Oxurion NV stock overvalued right now?
Oxurion NV (FRA:TG40) has a current Total Receivables of €0.38 Mil. The current Total Receivables is €0.38 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For Oxurion NV (FRA:TG40), the current Total Receivables is €0.38 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Oxurion NV Business Description

Other Exchanges TG40:GermanyOXUR:Belgium
Address Gaston Geenslaan 1, Leuven, BEL, B-3001
Oxurion NV is a holding company specializing in acquiring and integrating clinical research services companies (CROs) covering the full clinical research value chain across Europe.